Other Events ·
Nasdaq confirms Nexalin regained compliance with $1.00 minimum bid price requirement
NXLNexalin Technology, Inc.
Nexalin Technology, Inc. received formal notification from Nasdaq confirming regained compliance with the Minimum Bid Price Requirement of $1.00 per share as of September 30, 2026. This follows a conditional approval granted on September 25, 2026, which required the company to demonstrate bid price compliance by September 28, 2026, and meet a minimum stockholders' equity requirement of $2,500,000 by January 4, 2027. The company intends to take necessary steps to satisfy the equity requirement within the specified timeframe, allowing its common stock to continue trading on the Nasdaq Capital Market during the exception period. Failure to meet these conditions could result in delisting. Nexalin Technology operates in the medical device industry, developing neuromodulation therapies for chronic pain management.